“This relationship with Oxford Finance and SVB strengthens our monetary position and expands our money as we seek to drive the progression of our ImmTOR portfolio in the treatment of genes and autoimmune diseases,” said Brad Dahms, Selecta’s chief financial officer.”We are very happy to continue our appointments with SVB and we are very happy to marry Oxford Finance at this facility at such a vital time for Selecta.”
“We are very pleased with Selecta’s efforts to continue the progress of her ImmTOR platform,” Christopher A said.Herr, senior chief executive of Oxford Finance.” ImmTOR’s perspective on the treatment of genes and autoimmune diseases is a component of our strategy to fund cutting-edge life.science companies.”
“Selecta is driving significant progress in biological treatments through its ImmTOR platform,” said Ryan Roller, director of life sciences and healthcare at Silicon Valley Bank.”We are very happy to make our appointments with the Selecta team bigger and have the opportunity for the next phase of the company’s growth.”
About Selecta Biosciences, Inc. Selecta Biosciences, Inc. is a clinical-grade biotechnology company that aims to unleash the full perspective of biological cures based on its pioneering Immune Tolerance Platform (ImmTOR ™). Selecta is committed to using ImmTOR to prospectively improve the efficacy of biologics, enable redosing of important genetic therapies, and create new immunoccurrences for autoimmune diseases. Selecta’s complex level candidate product, SEL-212, is designed to be a monthly remedy for chronic refractory gout, a rare, debilitating disease with a significant unmet medical need. SEL-212 is comprised of a blend of its ImmTOR platform co-administered with pegadricase, an enzyme designed to treat patients with symptomatic gout refractory to the popular uric acid relief cure. Applicants for Selecta’s proprietary genetic healing products are progressing due to inborn errors of metabolism and are integrating our ImmTOR platform in order to overcome barriers to repeat administration. In addition to our own portfolio of basic discoveries and clinical applicants, Selecta has established collaborative relationships with leading biopharmaceutical companies, adding Asklepios BioPharmaceutical (AskBio) and Sarepta Therapeutics for genetic healing, and Swedish Orphan Biovitrum AB (Sobi ™) for SEL-212 . Selecta is founded in Watertown, Massachusetts. For more information, visit www.selectabio.com.
At Oxford Finance LLC Oxford Finance is a specialized financing company that offers leading secured loans to public and personal life sciences and fitness companies worldwide. For more than 20 years, Oxford has provided flexible financing responses to its clients, allowing those companies to maximize their capital by leveraging their assets. In recent years, Oxford has provided more than $6 billion in loans, with lines of credit ranging from $5 million to $150 million. Oxford is headquartered in Alexandria, Virginia, with more offices in San Diego, California; Palo Alto, California; and the main spaces in Boston and New York.For more information, scale https://oxfordfinance.com/.
At Silicon Valley Bank For more than 35 years, Silicon Valley Bank (SVB) has been helping state-of-the-art corporations and their investors move ambitious concepts forward quickly., foreign banking and personal Array SVB is helping to satisfy the unique desires of innovators.Learn more about svb.com.
Forward-Looking Statements All statements in this press release regarding the long-term expectations, plans and customers of Selecta Biosciences, Inc. (“the Company”), adding, without limitation, the company’s plans to use the proceeds of debt financing facilities, track the company’s liquidity, the company’s ability to expand its candidate products, the ImmTOR platform’s perspective on gene therapy and autoimmune disease indications and, in general, the ability of the company to reach milestones of progression, the company plans to access the additional $ 10 million to be under the debt financing line by achieving the milestones, time, enrollment and progress of the clinical trial programs of the Company, as well as the timing of interest payments and the Company’s ability to expand its strategic partnerships, the adequacy of the company’s money sa and money equivalents and short-term investments, and other statements that contain the words “anticipate”, “believe”, continue “,” could “,” estimate “,” expect “Matrix” speculate “,” pretend “,” possibly “,” plan “,” prospective “,” predict “,” project “,” deserve “,” Target “,” would “and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual effects may differ materially from those indicated through these forward-looking statements due to vital points, adding, but not limited to the following: the company’s ability to maintain its existing or long-standing collaborations, licenses or contractual relationships term, the availability of sufficient investment for your predictable and unpredictable operating expenses and capital expenditures, worth your common shares, adding aggregate inventory market fluctuations of s that occur as a result of the COVID-19 outbreak, and other vital points discussed in the “Risk Factors” segment of the company’s recent Maximum Quarterly Report on Form 10-Q, and in other submissions the company makes with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release constitute the Company’s views only as of the date of their publication and should not be construed as constituting its revisions at a later date. The company, in particular, rejects any objective of updating the forward-looking statements included in this press release.
For the media: Meredith Sosulski, Ph.D.LifeSci Communications, LLC [email protected]